Please sign in to follow a disease.
Xeltis
Clinical trials sponsored by Xeltis, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- First human trial of artificial bypass graft begins Results expected Feb 2027 (estimated)
- A regenerative graft could rethink dialysis access Results expected Jul 2027 (estimated)
-
Can a dissolving heart valve spare kids from repeat surgeries?
Disease control OngoingThis trial is testing a new type of heart valve made from a material that the body absorbs over time. It is designed for children and young adults who need surgery to fix a congenital heart defect affecting the passage from the heart to the lungs. The valve is implanted during su…
Sponsor: Xeltis • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
First human trial of artificial bypass graft begins
Disease control By invitation onlyThis early study tests a new synthetic blood vessel (XABG) for coronary artery bypass surgery in 20 people with multi-vessel heart disease. The graft is designed to work like a natural artery. Researchers are checking if it stays open and is safe in the first 30 days. This is a f…
Sponsor: Xeltis • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
New biodegradable graft could improve dialysis access for kidney patients
Disease control By invitation onlyThis study is testing a new type of graft (called aXess) for people with end-stage kidney disease who need hemodialysis but can't have a standard fistula. The graft is made of a biodegradable material that may help reduce complications. About 140 adults will be enrolled to see if…
Sponsor: Xeltis • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC